Episode 10: The New Frontier: CAR T-Cell Therapy and What the AP Needs to Know

Wendy Vogel, MSN, FNP, AOCNP

Victoria Reiser, RN, BSN, BMTCN, OCN

Victoria Reiser, RN, BSN, BMTCN, OCN, author of the JADPRO article Beyond CAR T-Cell Therapy: Continued Monitoring and Management of Complications speaks with co-host Wendy Vogel, MSN, FNP, AOCNP, on caring for patients who have received CAR T-cell therapy.

2:07 Introductions
3:42 If you had a billboard about your article, what would the headline be?
4:25 Why is this topic important for APs?
5:27 How would you explain CAR T-cell therapy to family members?
6:35 Infusion process
7:52 Monitoring for cytokine release syndrome
8:26 Immune effector cell-associated neurotoxicity syndrome (ICANS)
11:05 Inpatient vs. outpatient
11:35 Caregiver involvement
14:02 Hemophagocytic lymphohistiocytosis (HLH)
15:48 Recovery period
16:28 Long-term toxicities
17:34 Assessing response
18:18 Prophylaxis after therapy
19:30 COVID-19 advice for patients
20:52 Geriatric patients
22:15 Myths
23:42 What's the hardest thing about CAR T-cell therapy?